Floatz logo

Hs-It101

Melanoma (Excluding Uveal Melanoma)

Qingdao Sino-Cell Biomedicine Co., Ltd.Cell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Melanoma (Excluding Uveal Melanoma) cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS ICOS (INDUCIBLE T-CELL COSTIMULATORY, ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE, AILIM, CD278)) AND ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC
Xencor, Inc.
Phase 1CC
Infusion Of Hs-It101
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 2NR

Same molecule, other indications

Hs-It101 is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
melanomaDormant
C
Indicative ·
39 / 100
View asset →
neoplasmDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →